There is good evidence from randomised trials (RCTs) that treating high blood pressure is effective in reducing cardiovascular risk, but people with high blood pressure can find it difficult to take antihypertensive medication regularly.
1 The relationship between adherence and achieved blood pressure is far from clear.
A recent systematic review of RCTs of adherenceimproving strategies in hypertension showed that only 15 of 38 studies reported blood pressure as an outcome. 2 Previous studies in this field used either arbitrary categorical cut points or unreliable measures of adherence. [2] [3] [4] In this study, we aimed to investigate prospectively the relationship between medication adherence and blood pressure as continuous variables in people with uncontrolled hypertension.
Participants were 159 patients with uncontrolled hypertension (X150/90 mm Hg) from 21 general practices in the Bristol area, who we identified through a search on the practice computer. These patients were taking part in a RCT assessing nurseled adherence support in hypertension. The RCT took place between December 2001 and December 2002. 5 We used medical event monitoring systems (MEMS s , Aardex, Switzerland), which are electronic pill boxes that consist of a container similar to conventional drug bottles and a larger lid holding a microchip and a pressure release system. This system is activated each time a monitor is opened and closed, storing the exact date and time of each opening sequence, which can be downloaded onto a personal computer. We measured adherence over a 6-month period.
For cost reasons, we could only supply one electronic monitor per study participant. If participants were taking more than one antihypertensive drug, one preparation was chosen to be the 'index drug' according to an agreed protocol, which favoured diuretics (the recommended first-line treatment at the time) over beta blockers and other drugs. Accordingly, diuretics were the most common drug group dispensed from the electronic monitors (50.4%), followed by beta blockers (19.8%), calcium channel blockers (14.0%), angiotensin-converting enzyme (ACE) inhibitors (10.0%) and other drugs (5.7%). The doses dispensed from the electronic monitors were mostly once daily (94.4%). With regard to the total number of oral drug prescriptions, 20.9% of participants were prescribed 1-2 drugs (3-5 drugs: 56.1%; six or more drugs: 21.6%). Adherence was defined as 'timing compliance', which is the percentage of doses taken at the correct interval 725% (e.g. 2476 h for a oncedaily regimen and 1273 h for a twice-daily regimen). This is the strictest measure of adherence provided through electronic monitoring, because it takes account of the inter-dose intervals and also the number of tablets taken.
Blood pressure was measured at 6 months by practice nurses using standard protocols as per routine clinical practice. The relationship between timing compliance and achieved blood pressure was explored through scatterplots and calculation of correlation coefficients as well as multivariable linear regression models adjusting for the stratifying variables, that is, age, gender, total number of tablets, drug group and general practice.
Mean timing compliance was 88.7% (standard deviation (s.d.) 18.2%), which indicates that many study participants were able to take their tablets at the same time each day for the 6-month study period ( Figure 1 ). Timing compliance was not correlated with systolic or diastolic blood pressure at followup. Figure 1 shows no obvious patterns in the scatterplots for the relationship of timing compliance with systolic or diastolic blood pressure, using either parametric correlation coefficients (in both cases À0.02 with a margin of error of about 0.16) or Spearman's rank correlation coefficient (À0.09 and þ 0.03, respectively).
A regression model adjusted for the above stratifying variables also showed no evidence of an effect of timing compliance on blood pressure, with regression coefficients (expressed in mm Hg per 10 percentage point increase in timing compliance) of À0.1 (95% confidence interval (CI) À1.8 to þ 1.9) for systolic and À0.1 (95% CI À1.0 to þ 0.8) for diastolic blood pressure. Adjusting additionally for blood pressure at the start of the study (and thus effectively investigating the change in blood pressure) led to virtually identical results (data not shown).
In this study, we found no relationship between timing compliance and achieved blood pressure, with the above CIs enabling us to rule out clinically significant differences in blood pressure for a substantial (over 0.5 s.d.) increase in timing compliance. The strengths of this study are the use of electronic monitoring as the comparative 'gold standard' in adherence measurement, the use of continuous rather than categorical outcome measures to increase the precision of the results and a follow-up period of 6 months, which is long enough for Hawthorne effects to have decayed.
This study has limitations in that blood pressure recordings were taken at one point in time, and ambulatory blood pressure monitoring could have provided better data. For cost and feasibility reasons, we could only supply one electronic monitor per participant and it is possible that in those cases where participants were on more than one blood pressure-lowering drug, timing compliance was not generally as good as for the one that was monitored. In addition, there is potential for bias, because study participants were patients with uncontrolled hypertension who are unlikely to be representative of all hypertensives. However, this does not affect the internal validity of the study, but makes the results less generalisable because the study population may have higher rates of pharmacological nonresponse to blood pressure-lowering medication. The use of multivariable analysis reduced the impact of confounding; however, an explanation for our results inevitably remains the possibility of residual confounding masking a true relationship. There is also the issue of measurement error, which may have affected the results, although to minimise this risk, blood pressure measurements were conducted using British Hypertension Society Guidelines. 6 The main outcome in this study was timing compliance, which is the strictest measure of adherence. However, there was also no relationship between adherence and blood pressure when less strict measures of adherence were used such as 'correct dosing' (whether or not a tablet was taken at all on the day) or 'taking compliance' (the percentage of the prescribed number of doses taken over the study period, equivalent to a 'pill count') (data not shown).
Nearly one-third of the eligible population (29%) took part in the study. As baseline blood pressures in the study sample were close to our chosen cut point of greater or equal to 150/90 mm Hg, there is potential for response bias, as patients with higher blood pressure levels may have been less likely to take part.
The data clearly show that for some individuals inadequate blood pressure control relates to poor adherence, whereas in the majority it relates to nonresponse to treatment. For these individuals, other reasons for inadequate control need to be investigated. 7 A third group showed well-controlled blood pressure despite not taking treatment as prescribed, and this group might benefit from a trial without treatment.
Increasing adherence to medication in chronic disease has been identified as a major international priority. 8 This study highlights that in the case of antihypertensives, it is not entirely clear how closely to the prescribed regimen drugs from different classes have to be taken to achieve the desired effect of blood pressure lowering.
Poor adherence is often cited as an important issue to consider in patients who have not reached treatment targets. 7 However, there is little evidence about the relationship between adherence and blood pressure, and many past studies have used unreliable measures of adherence. 2 This study used the current 'gold standard', that is, electronic monitors, in the assessment of adherence. Our results indicate that, surprisingly, there is no clear relationship between adherence and blood pressure, at least among patients with reasonable adherence levels at baseline. In a recent systematic review, the majority of trials used cut points of 80 or 90% to define adherence. 2 Our data suggest that any single cut point is arbitrary and probably inappropriate. We need more studies that investigate the relationship between medication adherence and blood pressure. Specifically, these studies should use objective instruments that measure adherence in all drug classes as well as other factors not related to adherence, such as co-morbidity and co-medication.
In conclusion, we found that for participants recruited from primary care, timing compliance was not related to either systolic or diastolic blood pressure. The relationship between adherence to antihypertensive medication and blood pressure in primary care remains unclear. Health professionals need to know for each major drug class how closely medication has to be taken in relation to the prescribed regimen. This will enable them to have a more informed and rational discussion with patients about their treatment. 
